Figure 2. Difference in muscle sympathetic nerve activity (MSNA) response to sodium glucose cotransporter 2 inhibitors between patients with diabetes with and without heart failure.

Change in MSNA (burst frequency and burst incidence) absolute value and percentage reduction by 12 weeks administration of dapagliflozin was significantly higher in patients with diabetes and heart failure than patients with diabetes without heart failure. A, Changes in absolute MSNA (burst frequency) value by dapagliflozin. B, Changes in absolute MSNA (burst incidence) value by dapagliflozin. C, Percentage reduction in MSNA (burst frequency) after 12 weeks administration of dapagliflozin. D, Percentage reduction in MSNA (burst incidence) after 12 weeks administration of dapagliflozin. HF indicates heart failure. Unpaired‐t test were performed to compare differences between groups.